Dakang Medical operates a network of independent medical facilities specializing in blood purification services for kidney disease. The company focuses on providing advanced treatments such as hemodialysis, hemofiltration, and peritoneal dialysis, utilizing state-of-the-art medical technology. Dakang Medical emphasizes a patient-centered approach, aiming to create a warm and supportive environment to enhance the treatment experience for individuals suffering from nephropathy. In addition to its clinical services, Dakang Medical is involved in medical investment and the management of medical institutions, as well as offering brand operation services within the healthcare sector.
TBSTest Technology is a developer and manufacturer of integrated circuit automatic test equipment, specializing in solutions for semiconductor manufacturers. Founded in 2017 and headquartered in Beijing, China, with additional offices in Xi’an City, Shanghai, and Suwon, South Korea, the company offers a range of products including test boards, software solutions, and memory systems. TBSTest Technology also provides pre-sales and after-sales support for its equipment, accessories, and software systems, catering to clients in integrated circuit design and production, as well as scientific research institutions and educational organizations. The company is dedicated to advancing testing technology for ultra-large-scale integrated circuits, ensuring high-quality performance for enterprise users in the semiconductor industry.
Yihui Information is a high-tech enterprise with complete independent intellectual property rights
Private Equity Round in 2022
G7 has an installation base of 800,000 cargo vehicles throughout China. Through its proprietary hardware devices, the company is able to compile data for logistics companies and drivers on location, route optimization, fuel consumption, and cargo status (temperature, humidity, etc).
Sinomicro Medical is a medical device firm focused on the development of tumor ablation treatment with minimally invasive surgical robots.
Beijing Immunochina Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company focused on the research and development of chimeric antigen receptor (CAR) T-cell therapies and a lentiviral vector manufacturing platform aimed at treating malignant tumors. The company's pipeline includes therapies targeting CD19, which is prevalent in various B-lineage malignancies such as acute B-cell lymphoblastic leukemia and non-Hodgkin's lymphoma; B cell maturation antigen (BCMA) for multiple myeloma; and CD123, associated with leukemia blasts and stem cells. Additionally, Immunochina is conducting clinical studies on CAR-T cells for relapsed and refractory non-Hodgkin's lymphoma. Founded in 2015 and based in Beijing, the company also engages in the production of cell injections, cell therapy drugs, and offers services related to medical technology development and clinical research.
Provider of intelligent storage and logistics solutions intended to serve the medical field. The company's system is based on HIoT (Hospital Internet of Things) technology that integrates medical resources to increase the efficiency of medical staffs and decrease operational error rates.
Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.
HQ Education is an O2O education service platform.
Private Equity Round in 2019
RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, that focuses on the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. Established in 2008, RemeGen specializes in innovative biologics, including monoclonal antibodies and antibody-drug conjugates. Its key products under development include Telitacicept, which targets autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, and Disitamab Vedotin for various cancers. The company is also advancing other candidates like RC28 and RC88 for retinal conditions, alongside several pre-clinical products aimed at treating solid tumors. RemeGen operates primarily in China but also maintains laboratories and offices in Beijing and California, emphasizing its commitment to fulfilling the medical needs of patients with life-threatening conditions.
Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.
Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor small molecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level.
BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.
Beijing Zettastone Technology Co., Ltd. is a company based in Beijing, China, specializing in the development of solid-state drives (SSDs). The company focuses on creating SSDs that cater to the needs of personal computer manufacturers, data centers, and storage solution providers. By providing advanced storage technology, Zettastone aims to enhance performance and efficiency for its customers, offering solutions that are both easier to use and faster than traditional storage options.
Cambricon Technologies Corporation Limited creates core processor chips for various types of intelligent cloud servers, intelligent edge devices, and intelligent terminals. It offers terminal intelligent processor IPs, smart accelerator cards, and edge artificial intelligence acceleration cards; and Cambricon NeuWare, a software development platform for its cloud, edge, and end intelligent processor products. The company was founded in 2016 and is based in Beijing, China.
RobotLeo, founded in 2014 and based in Beijing, China, specializes in the manufacturing of intelligent companion robots for domestic use. The company is dedicated to the research and development of advanced robots that incorporate artificial intelligence and sensory technology. Its product offerings include family robots designed to engage in simple human interactions and provide on-demand personal care for both children and the elderly. Additionally, RobotLeo has developed a range of security surveillance solutions, featuring AI-powered smart patrol robots and 2D depth surveillance cameras. Through its innovative approach, RobotLeo aims to enhance daily life and safety in home environments.
Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.
Developer of cloud computing software in China. The company is mainly engaged in developing cloud computing software based on big data technology, providing users with comprehensive solutions from data storage, to data computing, and data analysis.
KBP Biosciences Co., Ltd. is a biotechnology company based in Jinan, China, with additional offices in Beijing, Japan, and the United States. Founded in 2002, the company focuses on the research and development of drugs targeting infectious and metabolic diseases. Its comprehensive research platform employs structure-based drug design, in vitro and cell-based biological screening, and pharmacodynamic and pharmacokinetic evaluation, alongside ADME profiling and pre-clinical animal pharmacology and toxicity analysis. KBP Biosciences also offers services related to the transfer of new drugs, licensing, and intellectual property protection, which includes patent scope analysis, novelty analysis, and patent writing and filing. The organization is committed to delivering innovative therapies to address unmet medical needs.
EnmoTech (Beijing) Information Technology Co., Ltd. specializes in data and database solutions, offering a range of products and professional services aimed at optimizing security and performance. Established in 2009 and located in Beijing, the company provides technical services such as distributed architecture, disaster recovery, SQL auditing, and performance monitoring. Its software offerings include platforms for IT system health inspection, database cloud service management, SQL quality control, and automated operation management. EnmoTech serves a diverse clientele across sectors including financial services, telecommunications, energy, public utilities, and manufacturing, focusing on delivering high-quality data services efficiently and cost-effectively.
Cambricon Technologies Corporation Limited creates core processor chips for various types of intelligent cloud servers, intelligent edge devices, and intelligent terminals. It offers terminal intelligent processor IPs, smart accelerator cards, and edge artificial intelligence acceleration cards; and Cambricon NeuWare, a software development platform for its cloud, edge, and end intelligent processor products. The company was founded in 2016 and is based in Beijing, China.
Eucure (Beijing) Biopharma Co., Ltd is a biotechnology company based in Beijing, China, specializing in the discovery and development of immuno-oncology targeted antibodies, particularly focusing on immune checkpoints. Founded in 2016, Eucure offers services including antibody production, in vivo drug efficacy testing, and in vitro efficacy evaluations. The company has a robust pipeline featuring multiple drug candidates, including YH-001 through YH-008. Several of these products have progressed to the CMC stage and have applied for clinical trials as of 2019. Eucure's mission is to create innovative antibody treatments aimed at improving survival rates for patients with tumors, reflecting its commitment to advancing cancer therapy. As of August 2020, Eucure operates as a subsidiary of Beijing Biocytogen Co., Ltd.
HiGo is a developer of intelligent driving control systems that aims to provide comprehensive solutions for autonomous vehicles. The company specializes in hardware, focusing on a central computing platform and chassis domain control platform. HiGo has positioned itself as a leader in the industry by launching self-driving electric sweepers designed for low-speed and fixed scenarios in China. This initiative not only showcases the company's technological capabilities but also contributes to the advancement of the autonomous driving sector.
Beijing SkyGuard Network Security Technologies LLC provides network information security technology services. The company was founded in 2015 and is based in Beijing, China.
Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.
Eucure (Beijing) Biopharma Co., Ltd is a biotechnology company based in Beijing, China, specializing in the discovery and development of immuno-oncology targeted antibodies, particularly focusing on immune checkpoints. Founded in 2016, Eucure offers services including antibody production, in vivo drug efficacy testing, and in vitro efficacy evaluations. The company has a robust pipeline featuring multiple drug candidates, including YH-001 through YH-008. Several of these products have progressed to the CMC stage and have applied for clinical trials as of 2019. Eucure's mission is to create innovative antibody treatments aimed at improving survival rates for patients with tumors, reflecting its commitment to advancing cancer therapy. As of August 2020, Eucure operates as a subsidiary of Beijing Biocytogen Co., Ltd.
Twenty First Century Aerospace Technology Co., Ltd specializes in commercial earth observation (EO) satellites and offers a wide array of data and information services. The company operates a constellation of small EO satellites capable of capturing high-resolution images and manages satellite control, image tasking, and receiving stations. Its comprehensive services encompass satellite procurement, operational management, data acquisition, image processing, and distribution, along with advanced geo-information services tailored for various applications. The company develops proprietary algorithms and software systems to ensure high-quality image data collection and processing. Its offerings include land cover imagery, change detection, data analysis, and 3D simulations, supporting sectors such as government administration, public services, and industrial applications. Founded in 2001 and based in Beijing, the company aims to leverage its technologies for applications in urban management, resource monitoring, disaster response, and environmental management, serving both Chinese and global markets.